Rx Rundown: Ferring Pharmaceuticals, Gilead Sciences, Artiva Biotherapeutics and more
Ferring Pharmaceuticals agreed to acquire Gameto for $1.4B. Gilead Sciences will buy PepStar Therapeutics' oral IL-23R inhibitor program for $1.275B. Zymeworks partnered with Roche for T-cell engager ZW209. Astellas secured an option to license Audax Biosciences' immuno-oncology asset. Teva finalized a Medicaid cost-lowering agreement. Pfizer's Talzenna gained FDA approval for prostate cancer. Artiva Biotherapeutics laid off 94% of its workforce. Star Therapeutics raised $200M in funding.
How this was made
The 30-second read
Why it matters
Collective deal flow suggests a bullish environment for sector players, but individual stock moves depend on deal specifics and execution risk.
Market read
Multiple high‑value deals and regulatory approvals could drive short‑term buying interest in the highlighted companies.
What to watch
Regulatory timelines and integration risks may delay any near‑term earnings impact.
Background
The article aggregates recent M&A, regulatory, and partnership news across the pharma and biotech sectors.
Ticker impact
Gilead announced acquisition of HCXT-2001 program from PepStar for $1.275 billion.
likely upward pressure as investors price in the new asset.
Large cash deal adds a promising oral IL‑23 inhibitor, enhancing Gilead's immunology franchise.
Zymeworks signed a global licensing and collaboration deal with Roche for ZW209.
moderate upside as market values the Roche partnership.
Roche partnership validates Zymeworks' T‑cell engager technology.
Bristol Myers Squibb partnered with Pathos AI and Tempus AI on AI tools for drug development.
minor upside as AI adoption is viewed favorably.
Strategic partnership without immediate financial commitment.
Teva finalized a Medicaid cost‑reduction agreement for select medicines.
mixed impact; potential slight downside from lower prices.
Government pricing pressure offsets any cost‑saving benefits.
Regeneron extended its BARDA agreement to supply more Ebola treatment Inmazeb.
modest upside as contract extension is viewed favorably.
Stable government contract adds to revenue visibility.
RadNet acquired Onrad.
potential upside as scale benefits are anticipated.
Integration risk and modest deal size limit impact.
AbbVie received FDA approval for a subcutaneous Skyrizi regimen for Crohn’s disease.
upward pressure as sales potential increases.
Regulatory approval adds a sizable new patient pool.
Pfizer expanded Talzenna approval in combination with Xtandi for prostate cancer.
moderate upside as market prices in larger indication.
Approval for a new combination therapy widens market reach.
Market effects
Healthcare M&A activity signals continued consolidation in biotech and pharma.
U.S. biotech sector may see modest uplift from multiple deal announcements.
International partners (Roche, Astellas) highlight cross‑border collaboration trends.
Counterpoint
Deal fatigue could pressure valuations; investors may wait for post‑integration results.
Key entities
- CompanyGilead Sciences
Acquirer of PepStar's IL‑23 program.
- CompanyZymeworks
Partnered with Roche on ZW209.
- CompanyAbbVie
Received FDA approval for Skyrizi subcutaneous regimen.
